262 related articles for article (PubMed ID: 18195160)
1. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients.
Savoia C; Touyz RM; Amiri F; Schiffrin EL
Hypertension; 2008 Feb; 51(2):432-9. PubMed ID: 18195160
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
Savoia C; Touyz RM; Endemann DH; Pu Q; Ko EA; De Ciuceis C; Schiffrin EL
Hypertension; 2006 Aug; 48(2):271-7. PubMed ID: 16785331
[TBL] [Abstract][Full Text] [Related]
3. Reduction of resistance artery stiffness by treatment with the AT(1)-receptor antagonist losartan in essential hypertension.
Park JB; Intengan HD; Schiffrin EL
J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):40-5. PubMed ID: 11967798
[TBL] [Abstract][Full Text] [Related]
4. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function.
Schiffrin EL; Park JB; Pu Q
J Hypertens; 2002 Jan; 20(1):71-8. PubMed ID: 11791028
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients.
Savoia C; Touyz RM; Volpe M; Schiffrin EL
Hypertension; 2007 Feb; 49(2):341-6. PubMed ID: 17159079
[TBL] [Abstract][Full Text] [Related]
6. Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertensive patients.
Schiffrin EL; Pu Q; Park JB
Am J Hypertens; 2002 Feb; 15(2 Pt 1):105-10. PubMed ID: 11863244
[TBL] [Abstract][Full Text] [Related]
7. Markers of inflammation, endothelial activation, and arterial stiffness in hypertensive heart disease and the effects of treatment: results from the SILVHIA study.
Jekell A; Malmqvist K; Wallén NH; Mörtsell D; Kahan T
J Cardiovasc Pharmacol; 2013 Dec; 62(6):559-66. PubMed ID: 24084214
[TBL] [Abstract][Full Text] [Related]
8. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
White WB; Duprez D; St Hillaire R; Krause S; Roniker B; Kuse-Hamilton J; Weber MA
Hypertension; 2003 May; 41(5):1021-6. PubMed ID: 12682082
[TBL] [Abstract][Full Text] [Related]
9. Effects of antihypertensive treatment on vascular remodeling in essential hypertensive patients.
Schiffrin EL; Deng LY; Larochelle P
J Cardiovasc Pharmacol; 1994; 24 Suppl 3():S51-6. PubMed ID: 7700067
[TBL] [Abstract][Full Text] [Related]
10. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
[TBL] [Abstract][Full Text] [Related]
11. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan.
Schiffrin EL; Park JB; Intengan HD; Touyz RM
Circulation; 2000 Apr; 101(14):1653-9. PubMed ID: 10758046
[TBL] [Abstract][Full Text] [Related]
12. Vascular changes in hypertension in response to drug treatment: Effects of angiotensin receptor blockers.
Schiffrin EL
Can J Cardiol; 2002 May; 18 Suppl A():15A-18A. PubMed ID: 12045789
[TBL] [Abstract][Full Text] [Related]
13. Structure and function of resistance arteries of hypertensive patients treated with a beta-blocker or a calcium channel antagonist.
Schiffrin EL; Deng LY
J Hypertens; 1996 Oct; 14(10):1247-55. PubMed ID: 8906525
[TBL] [Abstract][Full Text] [Related]
14. Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a beta-blocker.
Schiffrin EL; Deng LY; Larochelle P
Am J Hypertens; 1995 Mar; 8(3):229-36. PubMed ID: 7794571
[TBL] [Abstract][Full Text] [Related]
15. Structure and function of small arteries of essential hypertensive patients following chronic treatment with once-a-day nifedipine.
Schiffrin EL
Cardiology; 1997; 88 Suppl 3():20-6. PubMed ID: 9397289
[TBL] [Abstract][Full Text] [Related]
16. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Müller-Brunotte R; Kahan T; López B; Edner M; González A; Díez J; Malmqvist K
J Hypertens; 2007 Sep; 25(9):1958-66. PubMed ID: 17762662
[TBL] [Abstract][Full Text] [Related]
17. Eplerenone offsets cardiac and aortic adverse remodeling in spontaneously hypertensive rats.
Burla AK; Neves MF; Oigman W; Mandarim-de-Lacerda CA
Int J Cardiol; 2007 Jan; 114(1):64-70. PubMed ID: 16650491
[TBL] [Abstract][Full Text] [Related]
18. Effects of eplerenone versus losartan in patients with low-renin hypertension.
Weinberger MH; White WB; Ruilope LM; MacDonald TM; Davidson RC; Roniker B; Patrick JL; Krause SL
Am Heart J; 2005 Sep; 150(3):426-33. PubMed ID: 16169319
[TBL] [Abstract][Full Text] [Related]
19. Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
Endemann DH; Touyz RM; Iglarz M; Savoia C; Schiffrin EL
Hypertension; 2004 Jun; 43(6):1252-7. PubMed ID: 15117913
[TBL] [Abstract][Full Text] [Related]
20. Effects of Add-on Therapy Consisting of a Selective Mineralocorticoid Receptor Blocker on Arterial Stiffness in Patients with Uncontrolled Hypertension.
Shibata T; Tsutsumi J; Hasegawa J; Sato N; Murashima E; Mori C; Hongo K; Yoshimura M
Intern Med; 2015; 54(13):1583-9. PubMed ID: 26134187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
